Market Implications: The progress of this study could positively impact AstraZeneca’s stock performance by demonstrating the effectiveness of dapagliflozin in a new patient demographic.

A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

Today, AstraZeneca Canada and Plan International Canada are excited to announce 10 exceptional young leaders selected to join the 2025-2026 Eureka Fellowship for Youth Changemakers in Canada ...

Court of Appeal reinforces plausibility requirements for pharmaceutical patent validity claims The Court of Appeal's decision in Generics (UK) Limited & Others v AstraZeneca AB represents a ...

Find out about the dosage for Farxiga. You can also get the facts on the form, strengths, and how to take the drug.

Today, AstraZeneca Canada and Plan International Canada are excited to announce 10 exceptional young leaders selected to join the 2025-2026 Eureka Fellowship for Youth Changemakers in Canada (Eureka ...

TORONTO, July 17, 2025 /CNW/ - Today, AstraZeneca Canada and Plan International Canada are excited to announce 10 exceptional young leaders selected to join the 2025-2026 Eureka Fellowship for ...

This study could significantly impact AstraZeneca’s market position by potentially validating dapagliflozin’s broader use in heart failure treatment, influencing investor sentiment positively.